Travere Therapeutics price target raised to $43 from $31 at Stifel

Stifel analyst Alex Thompson raised the firm’s price target on Travere Therapeutics (TVTX) to $43 from $31 and keeps a Hold rating on the shares after the company reported that the FDA has approved Filspari. Despite some questions around the dataset/approvability, the unmet need in focal segmental glomerulosclerosis is clear; Stifel’s key opinion leader check post approval is consistent with Travere’s and the Street’s expectations for a rapid launch, the firm told investors in a research note.